{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T00:04:33Z","timestamp":1756166673259,"version":"3.44.0"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background and aims<\/jats:title>\n                  <jats:p>Pneumococcal vaccination is essential for patients with inflammatory bowel diseases (IBD), but its efficacy is reduced in those on antitumor necrosis factor (TNF) or immunosuppressive therapy. This study compared immune responses to standard versus intensified pneumococcal vaccination strategies in IBD patients receiving anti-TNF (\u00b1immunosuppressors) or vedolizumab.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>In a prospective, multicenter, randomized open-label study across 7 French university hospitals, IBD patients in clinical remission on biologic therapy (anti-TNF\u2005\u00b1\u2005immunosuppressors, or vedolizumab) were randomized 1:1 to an intensified (PCV13\/PCV13\/PPSV23) or standard (PCV13\/PPSV23) regimen. Vaccine response (ELISA and opsonophagocytic assays [OPA]), side effects, and disease activity were monitored over 36 months. The primary endpoint was vaccine response at month 5 (M5), defined as antibody titers &amp;gt;1 \u00b5g\/mL for at least 9 of 13 serotypes in ELISA.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>One hundred and four patients (median age, 43 years; 60.6% male; 68.3% Crohn\u2019s disease) were randomized to the standard (n\u2005=\u200551) or intensified (n\u2005=\u200553) regimen. At M5, the vaccine response was significantly higher in the intensified group compared to the standard group, as measured by ELISA (53.2% vs. 27.1%; relative risk [RR[\u2005=\u20051.96; 95% CI, 1.15\u20133.36; P\u2005=\u2005.009) and OPA (90.9% vs. 62.5%; P\u2005=\u2005.007). OPA responses remained higher in the intensified group at M12, M18, and M36. Reduced responses were associated with anti-TNF therapy, combination therapy, and Crohn\u2019s disease. Both regimens were well tolerated, with no differences in safety profiles or IBD relapse rates.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Intensified vaccination significantly enhances and sustains immune response over 36 months, particularly benefiting patients with CD on anti-TNF therapy.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ecco-jcc\/jjaf115","type":"journal-article","created":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T09:47:26Z","timestamp":1756115246000},"source":"Crossref","is-referenced-by-count":0,"title":["Comparing standard versus intensified pneumococcal vaccination regimens in patients with inflammatory bowel disease on biologics: a prospective, multicenter, randomized, open-label study"],"prefix":"10.1093","volume":"19","author":[{"given":"Xavier","family":"Roblin","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Saint-Etienne University Hospital , Saint-Etienne ,","place":["France"]},{"name":"CIRI (Centre International de Recherche en Infectiologie), Universit\u00e9 Claude Bernard Lyon 1, INSERM U1111, CNRS, UMR5308, ENS Lyon, Universit\u00e9 Jean Monnet de Saint- , Saint-Etienne ,","place":["France"]},{"name":"CIC1408, University Hospital of Saint-Etienne , Saint-Etienne ,","place":["France"]},{"name":"Institut priv\u00e9 des MICI , Echirolles ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1859-7146","authenticated-orcid":false,"given":"Sophie","family":"Vieujean","sequence":"additional","affiliation":[{"name":"Hepato-Gastroenterology and Digestive Oncology, University Hospital CHU of Li\u00e8ge , Li\u00e8ge ,","place":["Belgium"]},{"name":"Department of Gastroenterology, INFINY Institute, CHRU Nancy , F-54500 Vand\u0153uvre-l\u00e8s-Nancy ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"St\u00e9phane","family":"Nancey","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Lyon-Sud Hospital, Hospices Civils de Lyon, INSERM U1111, CIRI , Lyon ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xavier","family":"Hebuterne","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Clinical Nutrition, CHU of Nice and University C\u00f4te d\u2019Azur , Nice ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadia","family":"Arab-Hocine","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Clinical Nutrition, CHU of Nice and University C\u00f4te d\u2019Azur , Nice ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guillaume","family":"Savoye","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Univ Rouen Normandie, INSERM, ADEN UMR1073, \u201cNutrition, Inflammation and microbiota-gut-brain axis\u201d, CHU Rouen , Rouen F-76000 ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"St\u00e9phanie","family":"Viennot","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, University Hospital of Caen , Caen ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guillaume","family":"Bouguen","sequence":"additional","affiliation":[{"name":"CHU Rennes, Univ Rennes, INSERM, CIC1414, Institut NUMECAN (Nutrition Metabolism and Cancer) , F-35000 Rennes ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2337-2902","authenticated-orcid":false,"given":"Mathurin","family":"Fumery","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Amiens University Hospital, and PeriTox, UMR I-01, Univervsit\u00e9 de Picardie Jules Verne , Amiens ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerard","family":"Duru","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Saint-Etienne University Hospital , Saint-Etienne ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2773-7750","authenticated-orcid":false,"given":"Elisabeth","family":"Botelho-Nevers","sequence":"additional","affiliation":[{"name":"CIRI (Centre International de Recherche en Infectiologie), Universit\u00e9 Claude Bernard Lyon 1, INSERM U1111, CNRS, UMR5308, ENS Lyon, Universit\u00e9 Jean Monnet de Saint- , Saint-Etienne ,","place":["France"]},{"name":"CIC1408, University Hospital of Saint-Etienne , Saint-Etienne ,","place":["France"]},{"name":"Department of Infectious Disease, CHU Saint Etienne , Saint-Etienne ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne-Emmanuelle","family":"Berger","sequence":"additional","affiliation":[{"name":"CIRI (Centre International de Recherche en Infectiologie), Universit\u00e9 Claude Bernard Lyon 1, INSERM U1111, CNRS, UMR5308, ENS Lyon, Universit\u00e9 Jean Monnet de Saint- , Saint-Etienne ,","place":["France"]},{"name":"Immunology Laboratory, iBioThera, CHU Saint Etienne , Saint-Etienne ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernard","family":"Tardy","sequence":"additional","affiliation":[{"name":"CIC1408, University Hospital of Saint-Etienne , Saint-Etienne ,","place":["France"]},{"name":"Clinical Pharmacology and Clinical Research Unit, Saint-Etienne University Hospital , Saint-Etienne ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Mathieu","sequence":"additional","affiliation":[{"name":"University Clinic of Hepato-Gastroenterology, University Hospital , Grenoble ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mathilde","family":"Barrau","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Saint-Etienne University Hospital , Saint-Etienne ,","place":["France"]},{"name":"CIRI (Centre International de Recherche en Infectiologie), Universit\u00e9 Claude Bernard Lyon 1, INSERM U1111, CNRS, UMR5308, ENS Lyon, Universit\u00e9 Jean Monnet de Saint- , Saint-Etienne ,","place":["France"]},{"name":"CIC1408, University Hospital of Saint-Etienne , Saint-Etienne ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurent","family":"Peyrin-Biroulet","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, INFINY Institute, CHRU Nancy , F-54500 Vand\u0153uvre-l\u00e8s-Nancy ,","place":["France"]},{"name":"Division of Gastroenterology and Hepatology, McGill University Health Centre , Montreal, Quebec ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8830-4273","authenticated-orcid":false,"given":"Stephane","family":"Paul","sequence":"additional","affiliation":[{"name":"CIRI (Centre International de Recherche en Infectiologie), Universit\u00e9 Claude Bernard Lyon 1, INSERM U1111, CNRS, UMR5308, ENS Lyon, Universit\u00e9 Jean Monnet de Saint- , Saint-Etienne ,","place":["France"]},{"name":"CIC1408, University Hospital of Saint-Etienne , Saint-Etienne ,","place":["France"]},{"name":"Immunology Laboratory, iBioThera, CHU Saint Etienne , Saint-Etienne ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,8,25]]},"reference":[{"key":"2025082505472218800_CIT0001","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1038\/ajg.2015.284","article-title":"Inflammatory bowel disease patients are at increased risk of invasive pneumococcal disease: a nationwide Danish cohort study 1977-2013","volume":"110","author":"Kants\u00f8","year":"2015","journal-title":"Am J Gastroenterol."},{"key":"2025082505472218800_CIT0002","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1080\/23744235.2019.1638519","article-title":"Persistence of antibodies to pneumococcal conjugate vaccine compared to polysaccharide vaccine in patients with Crohn\u2019s disease\u2014one year follow up","volume":"51","author":"Kants\u00f8","year":"2019","journal-title":"Infect Dis (Auckl)"},{"key":"2025082505472218800_CIT0003","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1093\/ecco-jcc\/jjab052","article-title":"ECCO guidelines on the prevention, diagnosis, and management of infections in inflammatory bowel disease","volume":"15","author":"Kucharzik","year":"2021","journal-title":"J Crohn\u2019s Colitis"},{"key":"2025082505472218800_CIT0004","doi-asserted-by":"publisher","first-page":"11273","DOI":"10.3748\/wjg.v21.i40.11273","article-title":"Immunogenicity and mechanisms impairing the response to vaccines in inflammatory bowel disease","volume":"21","author":"Mar\u00edn","year":"2015","journal-title":"World J Gastroenterol."},{"key":"2025082505472218800_CIT0005","doi-asserted-by":"publisher","first-page":"835","DOI":"10.4103\/0366-6999.152683","article-title":"Effects of immunosuppressants on immune response to vaccine in inflammatory bowel disease","volume":"128","author":"Cao","year":"2015","journal-title":"Chin Med J (Engl)."},{"key":"2025082505472218800_CIT0006","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.crohns.2013.12.013","article-title":"Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease","volume":"8","author":"Rahier","year":"2014","journal-title":"J Crohn\u2019s Colitis"},{"key":"2025082505472218800_CIT0007","article-title":"Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine for Adults with Immunocompromising Conditions: Recommendations of the Advisory Committee on Immunization Practices (ACIP)","author":"Kobayashi"},{"key":"2025082505472218800_CIT0008","doi-asserted-by":"publisher","first-page":"e44","DOI":"10.1093\/cid\/cit684","article-title":"2013 IDSA clinical practice guideline for vaccination of the immunocompromised host","volume":"58","author":"Rubin","year":"2014","journal-title":"Clin Infect Dis."},{"key":"2025082505472218800_CIT0009","doi-asserted-by":"publisher","first-page":"462","DOI":"10.14309\/ajg.0000000000001619","article-title":"Factors affecting initial humoral immune response to SARS-CoV-2 vaccines among patients with inflammatory bowel diseases","volume":"117","author":"Kappelman","year":"2022","journal-title":"Am J Gastroenterol."},{"key":"2025082505472218800_CIT0010","doi-asserted-by":"publisher","first-page":"104788","DOI":"10.1016\/j.ebiom.2023.104788","article-title":"Lower magnitude and faster waning of antibody responses to SARS-CoV-2 vaccination in anti-TNF-\u03b1-treated IBD patients are linked to lack of activation and expansion of cTfh1 cells and impaired B memory cell formation","volume":"96","author":"Garner-Spitzer","year":"2023","journal-title":"eBioMedicine"},{"key":"2025082505472218800_CIT0011","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1038\/ajg.2009.523","article-title":"Immunosuppression impairs response to pneumococcal polysaccharide vaccination in patients with inflammatory bowel disease","volume":"105","author":"Melmed","year":"2010","journal-title":"Am J Gastroenterol."},{"key":"2025082505472218800_CIT0012","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1002\/ibd.21800","article-title":"Effects of immunosuppression on immune response to pneumococcal vaccine in inflammatory bowel disease: a prospective study","volume":"18","author":"Fiorino","year":"2012","journal-title":"Inflamm Bowel Dis."},{"key":"2025082505472218800_CIT0013","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.crohns.2013.09.022","article-title":"Patients with Crohn\u2019s disease on anti-tumor necrosis factor therapy are at significant risk of inadequate response to the 23-valent pneumococcal polysaccharide vaccine","volume":"8","author":"Lee","year":"2014","journal-title":"J Crohns Colitis."},{"key":"2025082505472218800_CIT0014","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1016\/j.crohns.2013.04.013","article-title":"When do we dare to stop biological or immunomodulatory therapy for Crohn\u2019s disease? Results of a multidisciplinary European expert panel","volume":"7","author":"Pittet","year":"2013","journal-title":"J Crohns Colitis."},{"key":"2025082505472218800_CIT0015","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.14309\/ajg.0000000000000289","article-title":"High immunogenicity of the pneumococcal conjugated vaccine in immunocompromised adults with inflammatory bowel disease","volume":"114","author":"Pittet","year":"2019","journal-title":"Am J Gastroenterol."},{"key":"2025082505472218800_CIT0016","doi-asserted-by":"publisher","first-page":"3884","DOI":"10.1016\/j.vaccine.2022.05.040","article-title":"Immunogenicity and safety of double dosage of pneumococcal vaccines in adult kidney transplant recipients and waiting list patients: a non-blinded, randomized clinical trial","volume":"40","author":"Larsen","year":"2022","journal-title":"Vaccine."},{"key":"2025082505472218800_CIT0017","doi-asserted-by":"publisher","first-page":"S66","DOI":"10.1097\/INF.0b013e318199f8ef","article-title":"Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine","volume":"28","author":"Vesikari","year":"2009","journal-title":"Pediatr Infect Dis J."},{"key":"2025082505472218800_CIT0018","doi-asserted-by":"publisher","first-page":"4192","DOI":"10.1016\/j.vaccine.2010.04.008","article-title":"Safety, tolerability, and immunologic noninferiority of a 13-valent pneumococcal conjugate vaccine compared to a 7-valent pneumococcal conjugate vaccine given with routine pediatric vaccinations in Germany","volume":"28","author":"Kieninger","year":"2010","journal-title":"Vaccine."},{"key":"2025082505472218800_CIT0019","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S1473-3099(18)30734-5","article-title":"Immunogenicity and reactogenicity of ten-valent versus 13-valent pneumococcal conjugate vaccines among infants in Ho Chi Minh City, Vietnam: a randomised controlled trial","volume":"19","author":"Temple","year":"2019","journal-title":"Lancet Infect Dis."},{"key":"2025082505472218800_CIT0020","doi-asserted-by":"publisher","first-page":"3387","DOI":"10.1016\/j.vaccine.2023.04.036","article-title":"A phase III, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of V114 compared with PCV13 in healthy infants (PNEU-PED-EU-1)","volume":"41","author":"Martinon-Torres","year":"2023","journal-title":"Vaccine."},{"key":"2025082505472218800_CIT0021","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1016\/j.vaccine.2015.02.026","article-title":"Vaccination status and immune response to 13-valent pneumococcal conjugate vaccine in asplenic individuals","volume":"33","author":"Nived","year":"2015","journal-title":"Vaccine."},{"key":"2025082505472218800_CIT0022","doi-asserted-by":"publisher","first-page":"3701","DOI":"10.1016\/j.vaccine.2018.05.012","article-title":"Pneumococcal conjugate vaccine triggers a better immune response than pneumococcal polysaccharide vaccine in patients with chronic lymphocytic leukemia: a randomized study by the Swedish CLL group","volume":"36","author":"Svensson","year":"2018","journal-title":"Vaccine."},{"key":"2025082505472218800_CIT0023","doi-asserted-by":"publisher","DOI":"10.4135\/9781483345727.n877","volume-title":"Pneumococcal vaccines WHO position paper.","author":"World Health Organization","year":"2013"},{"key":"2025082505472218800_CIT0024","doi-asserted-by":"publisher","first-page":"3816","DOI":"10.1016\/j.vaccine.2007.01.119","article-title":"Estimating the protective concentration of anti-pneumococcal capsular polysaccharide antibodies","volume":"25","author":"Siber","year":"2007","journal-title":"Vaccine."},{"key":"2025082505472218800_CIT0025","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.jaci.2012.07.002","article-title":"Use and interpretation of diagnostic vaccination in primary immunodeficiency: a working group report of the Basic and Clinical Immunology Interest Section of the American Academy of Allergy, Asthma & Immunology","volume":"130","author":"Orange","year":"2012","journal-title":"J Allergy Clin Immunol."},{"key":"2025082505472218800_CIT0026","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/S1081-1206(10)60572-8","article-title":"Assessment and clinical interpretation of polysaccharide antibody responses","volume":"99","author":"Paris","year":"2007","journal-title":"Ann Allergy Asthma Immunol."},{"key":"2025082505472218800_CIT0027","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/S1473-3099(14)70822-9","article-title":"Serotype-specific effectiveness and correlates of protection for the 13-valent pneumococcal conjugate vaccine: a postlicensure indirect cohort study","volume":"14","author":"Andrews","year":"2014","journal-title":"Lancet Infect Dis."},{"key":"2025082505472218800_CIT0028","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1093\/cid\/ciz226","article-title":"Immunogenicity of the currently recommended pneumococcal vaccination schedule in patients with inflammatory bowel disease","volume":"70","author":"Van Aalst","year":"2020","journal-title":"Clin Infect Dis."},{"key":"2025082505472218800_CIT0029","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/j.vaccine.2017.12.061","article-title":"Randomized clinical trial of a single versus a double dose of 13-valent pneumococcal conjugate vaccine in adults 55 through 74 years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine","volume":"36","author":"Jackson","year":"2018","journal-title":"Vaccine."},{"key":"2025082505472218800_CIT0030","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1007\/s10156-013-0601-1","article-title":"Pneumococcal vaccine and opsonic pneumococcal antibody","volume":"19","author":"Song","year":"2013","journal-title":"J Infect Chemother."},{"key":"2025082505472218800_CIT0031","doi-asserted-by":"publisher","first-page":"5464","DOI":"10.1016\/j.vaccine.2015.08.011","article-title":"Immunosuppressive drugs impairs antibody response of the polysaccharide and conjugated pneumococcal vaccines in patients with Crohn\u2019s disease","volume":"33","author":"Kants\u00f8","year":"2015","journal-title":"Vaccine."},{"key":"2025082505472218800_CIT0032","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/crocol\/otaa082","article-title":"The immunogenicity of the influenza, pneumococcal, and hepatitis B vaccines in patients with inflammatory bowel disease treated with vedolizumab","volume":"2","author":"Harrington","year":"2020","journal-title":"Crohns Colitis 360."},{"key":"2025082505472218800_CIT0033","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1136\/gutjnl-2021-324388","article-title":"Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab","volume":"70","author":"Kennedy","year":"2021","journal-title":"Gut."}],"container-title":["Journal of Crohn's and Colitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/19\/7\/jjaf115\/64118830\/jjaf115.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/19\/7\/jjaf115\/64118830\/jjaf115.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T09:47:27Z","timestamp":1756115247000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article\/doi\/10.1093\/ecco-jcc\/jjaf115\/8240569"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":33,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7,3]]}},"URL":"https:\/\/doi.org\/10.1093\/ecco-jcc\/jjaf115","relation":{},"ISSN":["1873-9946","1876-4479"],"issn-type":[{"value":"1873-9946","type":"print"},{"value":"1876-4479","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,7]]},"published":{"date-parts":[[2025,7]]},"article-number":"jjaf115"}}